Norberto Ortego-Centeno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8294083/publications.pdf

Version: 2024-02-01

139	4,714	109321	118850
papers	citations	35 h-index	62 g-index

171	171	171	6671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis. Journal of Clinical Densitometry, 2021, 24, 362-368.	1.2	2
2	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	1.6	8
3	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	3.3	4
4	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	3.3	12
5	Low-Dose Rituximab for Hemolytic Anemia Retreatment in a Patient With Systemic Lupus Erythematosus. American Journal of Therapeutics, 2018, 25, e577-e578.	0.9	0
6	Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter crossâ€sectional study. International Journal of Rheumatic Diseases, 2018, 21, 2028-2035.	1.9	8
7	Eosinofilia, exantema pruriginoso y necrosis digital. Medicina ClÃnica, 2018, 150, e17.	0.6	0
8	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Seminars in Arthritis and Rheumatism, 2018, 47, 849-857.	3.4	16
9	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clinical Rheumatology, 2018, 37, 999-1009.	2.2	27
10	T Cell Large Granular Lymphocyte Leukaemia with Cutaneous Infiltration. Sultan Qaboos University Medical Journal, 2018, 17, 489.	1.0	1
11	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
12	Association between perceived level of stress, clinical characteristics and psychopathological symptoms in women with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2018, 36, 434-441.	0.8	8
13	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	6.5	60
14	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	5.8	46
15	Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	5.6	9
16	New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. Journal of Medical Genetics, 2017, 54, 38-46.	3.2	18
17	A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 286-294.	0.9	58
18	Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. Autoimmunity Reviews, 2017, 16, 796-802.	5.8	16

#	Article	IF	Citations
19	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
20	Analyses of hair and salivary cortisol for evaluating hypothalamicâ€“pituitaryâ€“adrenal axis activation in patients with autoimmune disease. Stress, 2017, 20, 541-548.	1.8	15
21	Mutational profile of rare variants in inflammasome-related genes in BehÃ§et disease: A Next Generation Sequencing approach. Scientific Reports, 2017, 7, 8453.	3.3	29
22	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
23	Enfermedad venooclusiva y esclerosis sistÃ©mica. Medicina ClÃnica, 2017, 149, 320.	0.6	0
24	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Scientific Reports, 2017, 7, 5088.	3.3	44
25	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 40-47.	0.8	6
26	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 98-105.	0.8	8
27	Genetic Analysis with the Immunochip Platform in BehÃ§et Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci. PLoS ONE, 2016, 11, e0161305.	2.5	48
28	Serosal involvement in IgG4-related disease: report of two cases and review of the literature. Rheumatology International, 2016, 36, 1033-1041.	3.0	12
29	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	5.6	46
30	Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with SjÃ¶gren syndrome. Clinical Rheumatology, 2016, 35, 825-828.	2.2	4
31	Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.9	41
32	Groove sign. European Journal of Internal Medicine, 2016, 28, e3-e4.	2.2	1
33	Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis. American Journal of Therapeutics, 2016, 23, e1193-e1196.	0.9	17
34	Sclerostin serum levels in patients with systemic autoimmune diseases. BoneKEy Reports, 2016, 5, 775.	2.7	8
35	Interleukin 1 beta (IL1ÃŸ) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-SchÃ¶nlein purpura. Clinical and Experimental Rheumatology, 2016, 34, S84-8.	0.8	12
36	PTPN22 is not associated with BehÃ§et's disease. Study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. Clinical and Experimental Rheumatology, 2016, 34, S41-S45.	0.8	2

#	Article	IF	Citations
37	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	1.0	133
38	Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A â€œReal-Lifeâ€•Study. Journal of Osteoporosis, 2015, 2015, 1-7.	0.5	13
39	Association of HLA-B*41:02 with Henoch-SchÃ¶nlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	3.5	33
40	Specific association ofIL17Agenetic variants with panuveitis. British Journal of Ophthalmology, 2015, 99, 566-570.	3.9	6
41	PXKlocus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility geneABHD6. Annals of the Rheumatic Diseases, 2015, 74, e14-e14.	0.9	24
42	Brief Report: Association of HLAâ€“DRB1*01 With IgA Vasculitis (Henochâ€šSchÃ¶nlein). Arthritis and Rheumatology, 2015, 67, 823-827.	5.6	35
43	Anti-TNF-Î± therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Seminars in Arthritis and Rheumatism, 2015, 45, 361-368.	3.4	78
44	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
45	Variants of the IFI16 Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to BehÃ§et Disease. Journal of Rheumatology, 2015, 42, 695-701.	2.0	17
46	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-SchÃ¶nlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	3.5	11
47	Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. Journal of Rheumatology, 2015, 42, 2327-2331.	2.0	13
48	SomaticNLRP3mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases, 2015, 74, 603-610.	0.9	104
49	Lack of association of TNFAIP3 and JAK1 with BehÃ§et's disease in the European population. Clinical and Experimental Rheumatology, 2015, 33, S36-9.	0.8	4
50	Association of CCR5Î”32 and BehÃ§et's disease: new data from a case-control study in the Spanish population and meta-analysis. Clinical and Experimental Rheumatology, 2015, 33, S96-100.	0.8	1
51	Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and BehÃ§et's diseases. Clinical and Experimental Rheumatology, 2015, 33, S117-22.	0.8	24
52	Epistatic Interaction of ERAP1 and HLA-B in BehÃ§et Disease: A Replication Study in the Spanish Population. PLoS ONE, 2014, 9, e102100.	2.5	30
53	Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 477.	0.6	14
54	Mesenteric Inflammatory Venoocclusive Disease in a Patient with SjÃ¶grenâ€™s Syndrome. Case Reports in Medicine, 2014, 2014, 1-3.	0.7	3

#	Article	IF	Citations
55	Healthâ€Related Internet Use by Patients With Systemic Sclerosis and Other Autoimmune Diseases: Comment on the Article by van der Vaart et al. Arthritis Care and Research, 2014, 66, 334-334.	3.4	0
56	Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	5.6	29
57	Health-related Internet use by lupus patients in southern Spain. Clinical Rheumatology, 2014, 33, 567-573.	2.2	11
58	Influence of Psychological Stress on Headache in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 453-457.	2.0	2
59	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
60	GIMAP and BehÃ§et disease: no association in the European population: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1433-1434.	0.9	17
61	Analysis of Ancestral and Functionally Relevant CD5 Variants in Systemic Lupus Erythematosus Patients. PLoS ONE, 2014, 9, e113090.	2.5	15
62	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
63	Lack of association between IL6 gene and Henoch-SchÃ¶nlein purpura. Clinical and Experimental Rheumatology, 2014, 32, S141-2.	0.8	8
64	IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports, 2013, 40, 4851-4856.	2.3	15
65	Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. BMC Medical Genetics, 2013, 14, 52.	2.1	12
66	Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Cytokine, 2013, 62, 232-243.	3.2	37
67	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcetâ€™s disease. Human Immunology, 2013, 74, 230-233.	2.4	30
68	Evidence of association of theNLRP1gene with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 628-630.	0.9	23
69	Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators of Inflammation, 2013, 2013, 1-6.	3.0	47
70	Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: BehÃ§etâ€™s Disease, Sarcoidosis, and Noninfectious Uveitis. Mediators of Inflammation, 2013, 2013, 1-10.	3.0	45
71	Confirmation ofTNIP1but notRHOBandPSORS1C1as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.9	56
72	Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.9	30

#	Article	IF	Citations
73	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	2.9	104
74	HLA and non-HLA genes in BehÃ§etâ€™s disease: a multicentric study in the Spanish population. Arthritis Research and Therapy, 2013, 15, R145.	3.5	50
75	No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. PLoS ONE, 2013, 8, e72892.	2.5	4
76	Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. PLoS ONE, 2013, 8, e76777.	2.5	3
77	Evidence of New Risk Genetic Factor to Systemic Lupus Erythematosus: The UBASH3A Gene. PLoS ONE, 2013, 8, e60646.	2.5	27
78	Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis. Molecular Vision, 2013, 19, 638-43.	1.1	7
79	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. Clinical and Experimental Rheumatology, 2013, 31, 186.	0.8	0
80	Altered AKT1 and MAPK1 Gene Expression on Peripheral Blood Mononuclear Cells and Correlation with T-Helper-Transcription Factors in Systemic Lupus Erythematosus Patients. Mediators of Inflammation, 2012, 2012, 1-14.	3.0	26
81	Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 114-119.	0.9	62
82	Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein. Annals of the Rheumatic Diseases, 2012, 71, 1219-1226.	0.9	33
83	Association of theFCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients. DNA and Cell Biology, 2012, 31, 1671-1677.	1.9	18
84	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	2.9	98
85	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. Journal of Rheumatology, 2012, 39, 112-118.	2.0	8
86	Association study ofBAK1gene polymorphisms in Spanish rheumatoid arthritis and systemic lupus erythematosus cohorts. Annals of the Rheumatic Diseases, 2012, 71, 314-316.	0.9	2
87	Novel association of acid phosphatase locus 1*C allele with systemic lupus erythematosus. Human Immunology, 2012, 73, 107-110.	2.4	9
88	Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with systemic lupus erythematosus: A proteomic signature for circulating low-density granulocytes. Journal of Proteomics, 2012, 75, 1778-1791.	2.4	21
89	Manifestaciones otorrinolaringolÃ³gicas de las vasculitis sistÃ©micas. Acta OtorrinolaringolÃ³gica EspaÃ±ola, 2012, 63, 303-310.	0.4	9
90	Association Between â˜’174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases. DNA and Cell Biology, 2012, 31, 1486-1491.	1.9	17

#	Article	IF	Citations
91	Tongue infarction as first symptom of temporal arteritis. Rheumatology International, 2012, 32, 799-800.	3.0	12
92	Registry of the Spanish Network for Systemic Sclerosis: Clinical Pattern According to Cutaneous Subsets and Immunological Status. Seminars in Arthritis and Rheumatism, 2012, 41, 789-800.	3.4	92
93	Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population. Clinical and Experimental Rheumatology, 2012, 30, S29-33.	0.8	4
94	Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions. Clinical and Experimental Rheumatology, 2012, 30, 905-11.	0.8	14
95	Analysis of the REL polymorphism rs13031237 in autoimmune diseases. Annals of the Rheumatic Diseases, 2011, 70, 711-712.	0.9	18
96	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research and Therapy, 2011, 13, R112.	3.5	53
97	A rare polymorphism in Toll Like Receptor 2 is associated with systemic sclerosis phenotype and increases production of inflammatory mediators. Journal of Translational Medicine, 2011, 9, .	4.4	0
98	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.9	63
99	The Functional Polymorphism 844 A>G in FcÎ±RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. Journal of Rheumatology, 2011, 38, 446-449.	2.0	4
100	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genetics, 2011, 7, e1002178.	3.5	201
101	A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2011, 38, 2598-2601.	2.0	4
102	Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. Clinical and Experimental Rheumatology, 2011, 29, S12-6.	0.8	4
103	Effectiveness of Mycophenolic Acid in Refractory Pyoderma Gangrenosum. Journal of Clinical Rheumatology, 2010, 16, 346-347.	0.9	7
104	Identification of HAVCR1 gene haplotypes associated with mRNA expression levels and susceptibility to autoimmune diseases. Human Genetics, 2010, 128, 221-229.	3.8	18
105	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics, 2010, 42, 426-429.	21.4	351
106	Vitamin D Deficiency in a Cohort of Patients with Systemic Scleroderma from the South of Spain. Journal of Rheumatology, 2010, 37, 1355-1355.	2.0	38
107	Lack of Association Between TRAF1/C5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 131-135.	2.0	8
108	Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2331-2333.	2.0	3

#	Article	IF	Citations
109	Role of BANK1 Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 1502-1504.	2.0	4
110	Promoter Insertion/Deletion in the IRF5 Gene Is Highly Associated with Susceptibility to Systemic Lupus Erythematosus in Distinct Populations, But Exerts a Modest Effect on Gene Expression in Peripheral Blood Mononuclear Cells. Journal of Rheumatology, 2010, 37, 574-578.	2.0	32
111	Adalimumab Treatment for SAPHO Syndrome. Acta Dermato-Venereologica, 2010, 90, 301-302.	1.3	26
112	Long-Term Evolution of Cytophagic Histiocytic Panniculitis. Journal of Cutaneous Medicine and Surgery, 2010, 14, 136-140.	1.2	2
113	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	2.0	9
114	Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis. Human Immunology, 2010, 71, 525-529.	2.4	9
115	Recurrent Telangiectasias on the Cheek: Angiolupoid Sarcoidosis. American Journal of Medicine, 2010, 123, e7-e8.	1.5	16
116	Influence of CD40 rs1883832 Polymorphism in Susceptibility to and Clinical Manifestations of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2076-2080.	2.0	19
117	Lupus Pernio or Chilblain Lupus?. Chest, 2009, 136, 946-947.	0.8	7
118	Lack of Association Between STAT4 Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2009, 36, 1021-1025.	2.0	8
119	Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Human Molecular Genetics, 2009, 18, 3739-3748.	2.9	54
120	Alterations in episodic memory in patients with systemic lupus erythematosusâ˜†. Archives of Clinical Neuropsychology, 2008, 23, 157-64.	0.5	6
121	OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA. Annals of Allergy, Asthma and Immunology, 2008, 101, 556.	1.0	9
122	A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Human Molecular Genetics, 2008, 18, 569-579.	2.9	106
123	Adalimumab Therapy for Refractory Uveitis: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 613-614.	1.4	21
124	Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1305-1313.	2.0	39
125	Prevalence of exercise pulmonary arterial hypertension in scleroderma. Journal of Rheumatology, 2008, 35, 1812-6.	2.0	21
126	Use of rituximab in Wegener's granulomatosis: comment on the article by Wong. Nephrology Dialysis Transplantation, 2007, 22, 958-959.	0.7	4

#	Article	IF	Citations
127	Use of Adalimumab in Poststreptococcal Reactive Arthritis. Journal of Clinical Rheumatology, 2007, 13, 176.	0.9	10
128	MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Human Immunology, 2007, 68, 610-615.	2.4	33
129	Corticosteroids in preventing severe lupus flares: Do all patients have the same risk? Comment on the article by Tseng et al. Arthritis and Rheumatism, 2007, 56, 2098-2099.	6.7	0
130	Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 3080-3086.	6.7	47
131	Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells. Molecular Immunology, 2006, 43, 1029-1039.	2.2	21
132	Proteomic analysis of plasma from patients with systemic lupus erythematosus: Increased presence of haptoglobin Î±2 polypeptide chains over the Î±1 isoforms. Proteomics, 2006, 6, S282-S292.	2.2	51
133	Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. Clinical Rheumatology, 2006, 25, 407-408.	2.2	11
134	Treatment of therapy-resistant sarcoidosis with adalimumab. Clinical Rheumatology, 2006, 25, 596-597.	2.2	91
135	Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by Sildenafil. Liver Transplantation, 2006, 12, 690-691.	2.4	11
136	Pulmonary hypertension and exercise echocardiography. European Journal of Echocardiography, 2006, 7, 261-262.	2.3	3
137	Association of a functional singleâ€nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 219-224.	6.7	275
138	Etidronate and glucocorticoid induced osteoporosis. Journal of Rheumatology, 2005, 32, 199-200.	2.0	3
139	Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. Journal of Rheumatology, 2003, 30, 1657-8.	2.0	21